CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
探索多发性骨髓瘤中的细胞免疫治疗平台
英文原题：Exploring cellular immunotherapy platforms in multiple myeloma.
查看英文原题
Exploring cellular immunotherapy platforms in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管治疗平台取得了重大进展，大多数多发性骨髓瘤（MM）患者最终仍会复发并死于该疾病。在过去十年中开发的新型治疗选择中，基因工程化T细胞具有巨大潜力。细胞免疫疗法，包括嵌合抗原受体（CAR）T细胞，正迅速成为MM的有效治疗方式。来源于MM患者骨髓的骨髓浸润淋巴细胞（MILs）是过继性T细胞疗法的一种新型T细胞来源，能够强效且特异性地靶向骨髓瘤细胞。在这篇综述中，我们审视了细胞免疫疗法的最新创新，包括树突状细胞的使用，以及基于MILs、自然杀伤（NK）细胞和CAR-T 细胞的细胞工具，这些有望提高MM患者治疗的疗效和/或降低毒性。
展开英文摘要原文
Despite major advances in therapeutic platforms, most patients with multiple myeloma (MM) eventually relapse and succumb to the disease. Among the novel therapeutic options developed over the past decade, genetically engineered T cells have a great deal of potential. Cellular immunotherapies, including chimeric antigen receptor (CAR) T cells, are rapidly becoming an effective therapeutic modality for MM.
Marrow-infiltrating lymphocytes (MILs) derived from the bone marrow of patients with MM are a novel source of T cells for adoptive T-cell therapy, which robustly and specifically target myeloma cells. In this review, we examine the recent innovations in cellular immunotherapies, including the use of dendritic cells, and cellular tools based on MILs, natural killer (NK) cells, and CAR T cells, which hold promise for improving the efficacy and/or reducing the toxicity of treatment in patients with MM.
论文信息
- 作者
- Vo MC、Jung SH、Nguyen VT、Tran VD、Ruzimurodov N、Kim SK、Nguyen XH、Kim M
- 第一作者单位
- Institute of Research and Development, Duy Tan University, Danang, Viet Nam.
- 通讯作者单位
- Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.South Korea
- 文献类型
- 综述
- 期刊
- Heliyon2024 Mar 30
- 原文标识
- PubMed 38524535 · DOI 10.1016/j.heliyon.2024.e27892
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →